The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Recap by typeshit. Post by Abhishek Kothari 🇮🇳 on X.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
She compares GLP-1 drugs to laser eye surgery, epidurals and dishwashers, tools nobody calls cheating, in a blunt social post.
Williams explains how retatrutide's glucagon pathway works and cautions that knockoff Reta sold online is a real risk. FDA approval could come in late 2027 or 2028.
A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Loading…